Modality
Peptide
MOA
PLK4i
Target
AuroraA
Pathway
NF-κB
PTSDUrothelial CaSMA
Development Pipeline
Preclinical
~Mar 2020
→ ~Jun 2021
Phase 1
~Sep 2021
→ ~Dec 2022
Phase 2
Mar 2023
→ Aug 2025
Phase 2Current
NCT06180238
1,990 pts·Urothelial Ca
2023-03→2025-08·Not yet recruiting
1,990 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-08-058mo agoPh3 Readout· Urothelial Ca
2026-08-225mo awayEMA Filing· SMA
Trial Timeline
Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3
P2/3
Not yet…
Catalysts
Ph3 Readout
2025-08-05 · 8mo ago
Urothelial Ca
EMA Filing
2026-08-22 · 5mo away
SMA
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06180238 | Phase 2/3 | Urothelial Ca | Not yet recr... | 1990 | SRI-4 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Motarapivir | GSK | Preclinical | AuroraA | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| AMG-2597 | Amgen | Phase 2/3 | CD38 | |
| Riluinavolisib | Moderna | NDA/BLA | KIF18A | |
| BNT-8090 | BioNTech | Phase 2 | AuroraA | |
| ARG-6988 | Argenx | Preclinical | AuroraA | |
| Semamavacamten | Ideaya Bio | Phase 1/2 | AuroraA | |
| Cevinaritide | Praxis Precision | Phase 3 | AuroraA | |
| SND-4562 | Syndax | NDA/BLA | AuroraA | |
| Lisorapivir | Ultragenyx | Approved | AuroraA |